New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

By D. Haase, U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, Andrea Kundgen, M. Lübbert, R. Kunzmann, A. Giagounidis and 9 more. Blood, 2007

808 citations recorded by the source corpus.

Subfields: Hematology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/55cc5f5939824264a53b86ac1b55e28fcba60b50

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Malcovati
2. E. Hellström-Lindberg
3. P. Greenberg
4. D. Bowen
5. L. Adès
6. J. Schanz
7. J. Čermák
8. P. Fenaux

Citations in the corpus

• New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. (2012, background): “Subsets of patients with various patterns of complex karyotypes, according to number of abnormalities, make it evident that prognosis in these patients deteriorates with increasing numbers of abnormalities, reflecting the clonal evolution and genetic instability of the clone.(10) The prognostic clas”
• Acquired mutations in TET2 are common in myelodysplastic syndromes (2009, neutral): “del(4)(q24) TET2 PPA2 AK094561 FLJ20184 105.”
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, background): “Chromosomal abnormalities are observed in 50 to 60% of patients with MDS; the most frequent single cytogenetic abnormalities include del(5q), monosomy 7 or del(7q), trisomy 8, and del(20q).(55-58)”